News Related to Blood Disorders

Related coverage linked through entity extraction aliases.

New Drug Target Identified for Antibiotic-Resistant E. Coli Infections

Feb 18, 2026

University of Alberta researchers identified GlpG protease as a new drug target for treating antibiotic-resistant E. coli, which causes 250,000 UTI deaths annually. Inhibiting the protease prevented bacterial adhesion and biofilm formation in laboratory tests.

Zemcelpro Receives NUB Status 1 in Germany, Enabling Hospital Reimbursement Applications

Feb 16, 2026

ExCellThera's cell therapy Zemcelpro (dorocubicel) has been granted NUB Status 1 in Germany, allowing hospitals to apply for temporary supplementary reimbursement. 220 German hospitals have expressed interest in offering the therapy in 2026.